Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of idiopathic SFN (based on clinical and electrodiagnostic criteria).~* Each day for 7 days prior to Visit 2 (Washout) they must complete a modified Quadruple Visual Analogue Scale₁ showing moderate to severe pain (i.e. a daily mean rating score of ≥ 4).~* As the safety of pregabalin in pregnancy has not been established, females of childbearing potential must have a negative βHCG serum and agree to practice acceptable birth control methods.~* All subjects must have screening laboratory values that are within normal limits or abnormal values that are deemed not clinically significant by the Principle Investigator.~Exclusion Criteria:~* Have a psychological or psychiatric condition that may hinder their ability to provide important information~* History of psychosis, drug or alcohol abuse history within the last year~* Malignancy within the last 2 years (except skin cancer)~* Clinically significant conditions (including but not limited to cardiovascular or hepatic diseases), and seizure disorders.~* Subjects with an abnormal 2-hour glucose tolerance test (i.e., glucose \>7.8 mmol/l) will be excluded under clinically significant conditions as stated above.~* May not have participated in a previous trial of pregabalin, have a history of intolerance or hypersensitivity to pregabalin.~* Patients with renal impairment (CrCl \< 60 ml/min) will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).